IONIS PARTNER BIOGEN PRESENTS PHASE 2 CELIA DATA AT AAIC DEMONSTRATING MEANINGFUL CLINICAL OUTCOMES AND ROBUST TAU REDUCTION WITH DIRANERSEN IN EARLY ALZHEIMER’S DISEASE

Reuters · 1d ago

Please log in to view news